XOMA Royalty (XOMA) Share-based Compensation (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Share-based Compensation came in at $2.3 million in Q1 2026, up 15.03% year-on-year from $2.0 million in Q1 2025, and down 41.74% quarter-over-quarter from $3.9 million in Q4 2025.
XOMA Royalty (XOMA) Share-based Compensation (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Share-based Compensation across 17 years of filings, most recently posting $2.3 million for Q1 2026.
- Share-based Compensation for Q1 2026 came in at $2.3 million, up 15.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.1 million (down 14.55% YoY), and the FY2025 annual result was $9.3 million, down 10.08% from the prior year.
- Share-based Compensation came in at $2.3 million for Q1 2026 at XOMA Royalty, down from $3.9 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $3.9 million in Q4 2025 to a low of $100000.0 in Q2 2025.
- The 5-year median for Share-based Compensation is $2.2 million (2023), against an average of $1.9 million.
- Across the five-year window, Share-based Compensation jumped 237.1% in 2023 and plunged 96.28% in 2025, its largest moves.
- XOMA Royalty's Share-based Compensation stood at $988000.0 in 2022, then surged by 168.12% to $2.6 million in 2023, then declined by 17.86% to $2.2 million in 2024, then jumped by 79.92% to $3.9 million in 2025, then plunged by 41.74% to $2.3 million in 2026.
- The last three Share-based Compensation figures came in at $2.3 million (Q1 2026), $3.9 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 26.47 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 2.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.28 Mn |
| Mar 31, 2026 | 2.28 Mn |
| Dec 31, 2025 | 3.92 Mn |
| Dec 31, 2025 | 3.92 Mn |
| Sep 30, 2025 | 1.77 Mn |
| Sep 30, 2025 | 1.77 Mn |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 1.98 Mn |
| Mar 31, 2025 | 1.98 Mn |
| Dec 31, 2024 | 2.18 Mn |
| Dec 31, 2024 | 2.18 Mn |
| Sep 30, 2024 | 2.59 Mn |
| Sep 30, 2024 | 2.59 Mn |
| Jun 30, 2024 | 2.69 Mn |
| Jun 30, 2024 | 2.69 Mn |
| Mar 31, 2024 | 2.86 Mn |
| Mar 31, 2024 | 2.86 Mn |
| Dec 31, 2023 | 2.65 Mn |
| Dec 31, 2023 | 2.65 Mn |